Understanding Your Brain Tumor Diagnosis Report
When diagnosed with a brain tumor, your pathology report is essential to identifying a treatment options specific to your tumor type. In this webinar, you will: • Understand what pathology testing is, how it works and what it information it provides about your tumor • Discuss the role of biomarkers and molecular testing in diagnosis and treatment decisions • Learn about the components of your pathology report, how to understand it, and what to look for Dr. Arie Perry of the University of California, San Francisco (UCSF) discusses the importance of understanding your pathology report and how to interpret the results of your brain tumor tissue influence to best inform your treatment options. For more information, resources or support, visit the abta.org, call (800) 886-2282 or email [email protected].

Accessing Novel Brain Tumor Treatments Through Research & Clinical Trials

Imaging of brain tumors (part 1): metastases, glioblastoma and beyond...

Brain tumor 2022: Advance in diagnosis and treatment

Approach to diagnosis of glial neoplasms - Dr. Perry (UCSF) #NEUROPATH

Informed in 30 - Understanding Biomarker Testing

WEBINAR: Facing a Brain Tumor Recurrence with Resilience

Hepatology and Liver Transplantation Webinar | MASLD Highlights 2026

How to Become Clinical Trial Ready, Using the Optune Gio Device for GBM/rGBM & FORTE Clinical Trial

What to Know When Newly Diagnosed with Primary CNS Lymphoma

Wilson Science and Technology Forum Dr. Joshua J. Jacobs 5-22-26

Webinar: Stephen Bagley, MD - Liquid Biopsy for Brain Tumors: Recent Advances and Future Directions

Imaging features of meningiomas - Part 1

Advances in Diagnosis and Treatment of Pediatric Neuroinflammatory Conditions - Mary Karalius, MD

WEBINAR: Understanding Cognitive & Emotional Shifts From Brain Tumors

A Phase 2 Clinical Trial of Immune12 (ANZCTR)

An Introduction to Brain Tumours and Neuroanatomy | Dr. Ruman Rhaman

Genomic and Molecular Markers in Glioma : Where Are We Now?

ADD/ADHD | What Is Attention Deficit Hyperactivity Disorder?

KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson’s Disease (2025)

